Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC
Status:
Recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
This prospective, single-arm, multicenter, phase II trial enrolled 40 patients who underwent
surgery after three cycles of neoadjuvant therapy with camrelizumab, nab-paclitaxel, and
carboplatin. The MPR is the primary endpoint, and the pCR, the complete resection rate, the
objective response rate, the disease-free survival, adverse events, and quality of life are
the secondary endpoints. The exploratory endpoints will be used to establish a multiomics
artificial intelligence system for neoadjuvant therapy effect prediction and decision-making
assistance based on radiomics, metabolism, genetic, and clinic-pathological characteristics
and to explore drug resistance mechanisms.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators:
Guangdong Provincial People's Hospital Third Affiliated Hospital, Sun Yat-Sen University